Less than 10% of patients that would benefit from GLP-1 drugs such as Wegovy can access them, states the World Health Organization as it publishes its first recommendations on the medications.
Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for more widespread and fairer availability to these injectable treatments.
According to projections, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"The new guidelines recognises that excess weight is a lifelong illness that can be addressed with thorough and continuous support," stated its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are significant barriers to broad availability to the injections that can help people shift substantial weight, says the organization.
Skinny Jab Shortage
Even in the present best projected scenario, the manufacturing of GLP-1 therapies might only reach around 100 million people – under 10% of those who need them, as stated by the WHO.
The recommendation urges governments and firms to increase availability, by approaches such as voluntary licensing.
A patent on the active ingredient – the core component of a leading brand – is due to expire in several countries in 2026.
The Way Weight-Loss Jabs Function
GLP-1 drugs replicate a biological compound to delay gastric emptying, curb appetite and enhance the sense of being full so people reduce food intake.
Patients usually start to lose weight within a few weeks of commencing the weekly injections.
Research suggests people may regain a significant portion a year later of halting the drug, because their normal hunger come back.
Being carrying excess weight elevates your likelihood for experiencing health problems, including diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight affects people in all nations and was responsible for millions of deaths worldwide in 2024, according to the health agency.
